Human immunoglobulin against hepatitis B (Immunoglobulinum contra hepatitidem B)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Immunoglobulins

Included in the formulation
  • Antigope®
    solution w / m 
    MICROGEN FGUP Scientific and Production Association     Russia
  • Neohepatect
    solution d / infusion 
    Biotest Pharma GmbH     Germany
    • АТХ:

    J.06.B.B.04   Human immunoglobulin against hepatitis B

    Pharmacodynamics:

    Specific immunoglobulin for intravenous administration against hepatitis B. Contains antibodies to the surface antigens of group B hepatitis. Reduces the risk of infection by blocking the receptors of the virus.

    Pharmacokinetics:

    After intravenous administration, the bioavailability of the drug is 100%. It is redistributed between blood plasma and extravascular space, reaching equilibrium in 3-5 days.

    The half-life is 24 days. It is disposed of by cells of the reticuloendothelial system.

    Indications:

    It is used for passive immunization in case of emergency prophylaxis of hepatitis B after being wounded with medical instruments used for working with patients infected with hepatitis B or after contact of mucous membranes with infected biological fluids: blood, serum, plasma, urine, saliva.

    Used to prevent hepatitis B in newborns born from mothers of carriers of HbsAg; for people with an increased risk of infection, as well as liver transplantation in patients with positive HbsAg.

    ICD-10

    XXI.Z20-Z29.Z20.5   Contact with the patient and the possibility of contracting viral hepatitis

    XXI.Z20-Z29.Z24.6   The need for immunization against viral hepatitis

    Contraindications:

    Individual intolerance.

    Carefully:

    Severe renal insufficiency, elderly age.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. It is used in pregnancy and lactation only for life indications.

    Dosing and Administration:

    Use in children

    Immediately after birth, intravenously administered intravenously 20-50 ME / kg, but not less than 100 ME (2 ml) followed by vaccination against hepatitis B.

    Adults

    Intravenously once 0.14 ml (7 IU) / kg, not less than 10 ml. If the risk of infection is constant, repeated administration of the drug at the same dosage with an interval of 1 month is recommended.

    When liver transplantation occurs in carriers of HbsAg during the operation, 200 ml (10,000 IU) is injected immediately after removal of the liver. After the operation: daily for 7 days to 40 ml (2 000 IU). The duration of the course is at least 6 months.

    The highest daily dose: 200 ml (10 000 IU).

    The highest single dose: 200 ml (10 000 IU).

    Side effects:

    Central and peripheral nervous system: headache, dizziness, rarely - hallucinations.

    The cardiovascular system: tachycardia, arterial hypotension, cyanosis, dyspnea, chest pain, tides, chills.

    Digestive system: abdominal pain, diarrhea.

    Musculoskeletal system: myalgia.

    Dermatological reactions: Hyperhidrosis.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Immunoglobulin should not be mixed in the same volume with any other medicines.

    Reduces the effectiveness of active immunization against rubella, chicken pox, measles, mumps. It is recommended to use antiviral vaccines 3 months after the application of immunoglobulin against hepatitis B.

    Special instructions:

    Monitoring serum creatinine content, control of diuresis.

    Instructions
    Up